JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257668

Human SETD7 (SET7) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

SETD7 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2.
4 Images
Western blot - Human SETD7 (SET7) knockout HeLa cell lysate (AB257668)
  • WB

Lab

Western blot - Human SETD7 (SET7) knockout HeLa cell lysate (AB257668)

Blocking and dilution buffer : Intercept® (TBS) Blocking Buffer diluted with an equal volume of 0.1% TBST

Lane 1 : Wild-type HeLa cell lysate (20 ug)
Lane 2 : SETD7 knockout HeLa cell lysate (20 ug)
Lane 3 : Jurkat cell lysate (20 ug)

Lanes 1-3 : Merged signal (red and green). Green - ab274416 observed at 50 kDa. Red - loading control ab8245 observed at 36 kDa.

ab274416 Anti-SET7 antibody [EPR23775-142] was shown to specifically react with SET7 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265770 (knockout cell lysate ab257668) was used. Wild-type and SET7 knockout samples were subjected to SDS-PAGE. ab274416 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated at room temperature for 2. 5 hours at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-SET7 antibody [EPR23775-142] (<a href='/en-us/products/primary-antibodies/set7-antibody-epr23775-142-ab274416'>ab274416</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

SET7 knockout HeLa cell lysate at 20 µg

Lane 3:

Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG H&L (IRDye® 800CW) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) and Goat Anti-Mouse IgG H&L (IRDye® 680RD) (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-irdye-680rd-preadsorbed-ab216776'>ab216776</a>) at 1/10000 dilution

Predicted band size: 41 kDa

Observed band size: 50 kDa

false

Western blot - Human SETD7 (SET7) knockout HeLa cell lysate (AB257668)
  • WB

Lab

Western blot - Human SETD7 (SET7) knockout HeLa cell lysate (AB257668)

Lane 1 : Wild-type HeLa cell lysate (20 ug)
Lane 2 : SETD7 knockout HeLa cell lysate (20 ug)
Lane 3 : U-2 OS cell lysate (20 ug)

ab124708 was shown to specifically react with SET7 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265770 (knockout cell lysate ab257668) was used. Wild-type and SET7 knockout samples were subjected to SDS-PAGE. ab124708 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated at room temperature for 2.5 hours at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-SET7 antibody [EPR5574] (<a href='/en-us/products/primary-antibodies/set7-antibody-epr5574-ab124708'>ab124708</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

SETD7 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human SETD7 (SET7) knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-setd7-set7-knockout-hela-cell-line-ab265770'>ab265770</a>)

Lane 3:

U-2 OS cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 41 kDa

Observed band size: 50 kDa

false

Sanger Sequencing - Human SETD7 (SET7) knockout HeLa cell lysate (AB257668)
  • Sanger seq

Unknown

Sanger Sequencing - Human SETD7 (SET7) knockout HeLa cell lysate (AB257668)

Allele-1 : 1 bp deletion in exon2

Sanger Sequencing - Human SETD7 (SET7) knockout HeLa cell lysate (AB257668)
  • Sanger seq

Unknown

Sanger Sequencing - Human SETD7 (SET7) knockout HeLa cell lysate (AB257668)

Allele-2 : 1 bp insertion in exon2

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2.

Disease

Adenocarcinoma

style
left-column

Complementary Products

Primary Antibodies

AB124708

Anti-SET7 antibody [EPR5574]

RabMAb|Recombinant|KO Validated

Immunoprecipitation - Anti-SET7 antibody [EPR5574] (AB124708)

  • 0
  • 0
Proteins & Peptides

AB51285

Recombinant Human SET7 protein (Tag Free)

Western blot - Recombinant Human SET7 protein (Tag Free) (AB51285)

  • 0
  • 0
Proteins & Peptides

AB259412

Recombinant human VEGF 165A protein (Active)

Premium Bioactive

Mass Spectrometry - Recombinant human VEGF 165A protein (Active) (AB259412)

  • 0
  • 0
Proteins & Peptides

AB180317

Recombinant Human POLR1C protein (His tag N-Terminus)

SDS-PAGE - Recombinant Human POLR1C protein (His tag N-Terminus) (AB180317)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257668-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human SETD7 knockout HeLa cell lysate", "number":"AB257668-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB257668-CMP02", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
SETD7
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SET7 also known as SETD7 or KMT7 is a lysine methyltransferase that adds methyl groups to lysine residues on target proteins influencing their function and stability. This protein has a molecular mass of approximately 55 kDa. SET7 is expressed in a variety of tissues including the heart liver and pancreas suggesting its versatile role across different biological systems.
Biological function summary

SET7 contributes to gene regulation by methylating histone H3 at lysine 4 (H3K4) a mark generally associated with transcriptional activation. It also methylates non-histone proteins such as p53 TAF10 and STAT3 affecting their activity and interactions. SET7 operates distinctively and does not need to be part of any complex to fulfill its function effectively in diverse cellular processes.

Pathways

SET7 modulates transcriptional pathways such as the p53 signaling pathway and the NF-kB pathway. It interacts with the p53 protein affecting cell cycle regulation and the response to DNA damage. The modification of NF-kB by SET7 can influence inflammation and immune responses. Through these pathways SET7 plays a role in maintaining cellular homeostasis and response to stress.

SET7 is involved in conditions like cancer and cardiovascular diseases. Its methylation of p53 links it to tumor suppression activities while its impact on NF-kB relates to inflammatory responses. Dysregulation of SET7 activity can lead to abnormal cell proliferation and inflammation pointing to its potential as a target for therapeutic intervention.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com